Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis

Peace Johnson; Amy Hajari Case

首页> 外文期刊>BMJ Open Respiratory Research >Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis

【24h】

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis

机译：Nintedanib在特发性肺纤维化患者中的临床应用

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Abstract Idiopathic pulmonary fibrosis (IPF) is a rare lung disease characterised by progressive loss of lung function, dyspnoea and cough. IPF has a variable clinical course but a poor prognosis. Nintedanib, a tyrosine kinase inhibitor, is one of two dru

机译：摘要特发性肺纤维化（IPF）是一种罕见的肺部疾病，其特征是肺功能逐渐丧失，呼吸困难和咳嗽。 IPF的临床病程可变，但预后较差。 Nintedanib是一种酪氨酸激酶抑制剂，是两种药物之一

著录项

来源
《BMJ Open Respiratory Research》 |2017年第1期|共页
作者
Peace Johnson; Amy Hajari Case;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类临床医学;
关键词

相似文献

外文文献
中文文献
专利

1. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry [J] . Colin H. Holtze, Elizabeth A. Freiheit, Susan L. Limb, Respiratory Research . 2020,第1期

机译：与Pirfenidone和Nintedanib在美国的患者和网站特征;患有肺纤维化基患者登记处的特发性肺纤维化患者分析
2. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials [J] . Lisa Lancaster, Bruno Crestani, Paul Hernandez, BMJ Open Respiratory Research . 2019,第1期

机译：Nintedanib治疗的特发性肺纤维化患者的安全性和生存数据：来自六个临床试验的汇总数据
3. Relationship between nintedanib exposure, clinical efficacy and adverse events in patients with idiopathic pulmonary fibrosis (IPF) [J] . Schmid U., Weber B., Dallinger C., Journal of pharmacokinetics and pharmacodynamics . 2016,第Suppla期

机译：Nintedanib暴露，特发性肺纤维化（IPF）患者的临床疗效与不良事件之间的关系
4. IDIOPATHIC PULMONARY FIBROSIS: DESCRIPTION OF CLINICAL PRESENTATION [C] . Brendan M Corcoran American College of Veterinary Internal Medicine Forum . 2008

机译：特发性肺纤维化：临床介绍的描述
5. Correlation of Vascular Leak Measured Using Gadofosveset-Enhanced Lung Magnetic Resonance Imaging with Radiographic and Physiologic Measures of Fibrosis in Patients with Idiopathic Pulmonary Fibrosis. [D] . Liang, Lloyd. 2018

机译：特发性肺纤维化患者使用Gadofosveset增强肺磁共振成像测得的血管渗漏与纤维化的放射学和生理学指标的相关性。
6. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry [O] . Colin H. Holtze, Elizabeth A. Freiheit, Susan L. Limb, 2020

机译：在美国使用吡非尼酮和nintedanib相关的患者和部位特征；肺纤维化基金会患者登记处登记的特发性肺纤维化患者的分析
7. Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy [O] . Masahiro Tahara, Keishi Oda, Kei Yamasaki, 2019

机译：用氧疗法治疗特发性肺纤维化患者肺动脉高压的时间超声脑高血压评估

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis

摘要

著录项

相似文献

相关主题

期刊订阅